drugset / Trial / NCT01335607

A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)

NCT01335607

Phase 1 Completed 12 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to: * Assess the relative bioavailability of 2 oral formulations of samatasvir (capsule and tablet prototype test formulation) * Compare the amount of study drug that is in the blood after taking either the capsule form of the drug or the tablet form of the drug while fasting. * Determine the amount of study drug that is in the blood after eating a meal. * Evaluate the safety of the tablet form of samatasvir in healthy people.

Timeline

Start
2011-04
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Samatasvir Small molecule 100 mg Oral